Literature DB >> 12556204

The not-so innocent bystander: the microenvironment as a therapeutic target in cancer.

Anna C Erickson1, Mary Helen Barcellos-Hoff.   

Abstract

The microenvironment in which cancer arises is often regarded as a bystander to the clonal expansion and acquisition of malignant characteristics of the tumour. However, a major function of the microenvironment is to suppress cancer, and its disruption is required for the establishment of cancer. In addition, tumour cells can further distort the microenvironment to promote growth, recruit non-malignant cells that provide physiological resources, and facilitate invasion. In this review, the authors discuss the contribution of the microenvironment, i.e., the stroma and its resident vasculature, inflammatory cells, growth factors and the extracellular matrix (ECM), in the development of cancer, and focus on two components as potential therapeutic targets in breast cancer. First, the ECM, which imparts crucial signalling via integrins and other receptors, is a first-line barrier to invasion, modulates aggressive behaviour and may be manipulated to provide novel impediments to tumour growth. Second, the authors discuss the involvement of TGF-beta1 as an example of one of many growth factors that can regulate ECM composition and degradation and that play complex roles in cancer. Compared to the variable routes taken by cells to become cancers, the response of tissues to cancer is relatively consistent. Therefore, controlling and eliminating cancer may be more readily achieved indirectly via the tissue microenvironment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12556204     DOI: 10.1517/14728222.7.1.71

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  16 in total

1.  Radiation-induced bystander effects: evidence for an adaptive response to low dose exposures?

Authors:  Carmel Mothersill; Colin Seymour
Journal:  Dose Response       Date:  2006-08-25       Impact factor: 2.658

2.  Effect of fibroblast activation protein and alpha2-antiplasmin cleaving enzyme on collagen types I, III, and IV.

Authors:  Victoria J Christiansen; Kenneth W Jackson; Kyung N Lee; Patrick A McKee
Journal:  Arch Biochem Biophys       Date:  2006-11-17       Impact factor: 4.013

Review 3.  Live-cell imaging of tumor proteolysis: impact of cellular and non-cellular microenvironment.

Authors:  Jennifer M Rothberg; Mansoureh Sameni; Kamiar Moin; Bonnie F Sloane
Journal:  Biochim Biophys Acta       Date:  2011-08-05

4.  Stromal markers AKR1C1 and AKR1C2 are prognostic factors in primary human breast cancer.

Authors:  Antonia Wenners; Felix Hartmann; Arne Jochens; Anna Maria Roemer; Ibrahim Alkatout; Wolfram Klapper; Marion van Mackelenbergh; Christoph Mundhenke; Walter Jonat; Maret Bauer
Journal:  Int J Clin Oncol       Date:  2015-11-14       Impact factor: 3.402

Review 5.  Proteoglycans: master modulators of paracrine fibroblast-carcinoma cell interactions.

Authors:  Andreas Friedl
Journal:  Semin Cell Dev Biol       Date:  2009-11-28       Impact factor: 7.727

6.  Increased blood clotting, microvascular density, and inflammation in eotaxin-secreting tumors implanted into mice.

Authors:  Michael Samoszuk; Tom Deng; Mark J Hamamura; Min-Ying Su; Nicholas Asbrock; Orhan Nalcioglu
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

7.  Post-transplantation malignancy: a cell autonomous mechanism with implications for therapy.

Authors:  Manikkam Suthanthiran; Minoru Hojo; Mary Maluccio; Daniel J Boffa; Fu L Luan
Journal:  Trans Am Clin Climatol Assoc       Date:  2009

8.  The molecular genetics of breast cancer and targeted therapy.

Authors:  Rachel Suter; James A Marcum
Journal:  Biologics       Date:  2007-09

Review 9.  Imaging and quantifying the dynamics of tumor-associated proteolysis.

Authors:  Mansoureh Sameni; Dora Cavallo-Medved; Julie Dosescu; Christopher Jedeszko; Kamiar Moin; Stefanie R Mullins; Mary B Olive; Deborah Rudy; Bonnie F Sloane
Journal:  Clin Exp Metastasis       Date:  2008-12-13       Impact factor: 5.150

10.  Heterogeneity of gene expression in stromal fibroblasts of human breast carcinomas and normal breast.

Authors:  M Bauer; G Su; C Casper; R He; W Rehrauer; A Friedl
Journal:  Oncogene       Date:  2010-01-11       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.